SPY424.48-0.78 -0.18%
DIA343.41-0.89 -0.26%
IXIC14,072.86-101.29 -0.71%

Checkpoint Therapeutics Completes Enrollment for Evaluation of Potential Cancer Treatment

05/12/2021 05:45

09:28 AM EDT, 05/12/2021 (MT Newswires) -- Checkpoint Therapeutics (CKPT) said Wednesday it completed enrollment for its registration-enabling clinical trial of cancer treatment candidate cosibelimab.

Top-line results are expected in Q4, and upon a successful outcome, the company plans to submit a biologics license application for cosibelimab in the first half of 2022, as well as a marketing authorization application in Europe.

Price: 2.4102, Change: -0.09, Percent Change: -3.59